| 0 (0%) | 11-10 12:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.22 |
1-year : | 10.77 |
| Resists | First : | 7.9 |
Second : | 9.22 |
| Pivot price | 1.05 |
|||
| Supports | First : | 3.17 |
Second : | 0.25 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 0.95 |
| MA(100) : | 8.76  |
MA(250) : | 14.44 |
|
| MACD | MACD : | -0.7 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 48 |
| RSI | RSI(14): 76.3 |
|||
| 52-week | High : | 110.48 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NCI ] has closed above the upper band by 43.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 27.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.57 - 0.58 | 0.58 - 0.58 |
Tue, 10 Nov 2026
What Lifted Neo-Concept (NASDAQ:NCI) by 60.37% Among the Top Market Movers on November 10, 2026? - kalkine.ca
Tue, 10 Nov 2026
Emad Shash: NCI BGO 2026 – Everything I Believe Modern Oncology Should Represent - Oncodaily
Mon, 09 Nov 2026
NCI Division of Cancer Prevention Congratulates Phil Castle on His Appointment as NCI Associate Director for Prevention - Oncodaily
Mon, 09 Nov 2026
AMRC: Revenue and operating income grew, but lower tax benefits and higher NCI reduced attributable earnings - TradingView
Mon, 09 Nov 2026
NCI Releases First Publicly Available Tissue Microarray Panel of Patient-Derived Pancreatic Cancer Models - Oncodaily
Sat, 07 Nov 2026
Anthony Letai Announces Dr. Phil Castle’s Appointment as Associate Director for Prevention at NCI - Oncodaily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 8 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 160 (K) |
| EPS | -1.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.67 |
| Profit Margin | -8.2 % |
| Operating Margin | -18.8 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | -13.3 % |
| Qtrly Rev. Growth | -7.5 % |
| Gross Profit (p.s.) | 5.35 |
| Sales Per Share | 15.91 |
| EBITDA (p.s.) | -0.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.88 |
| PEG Ratio | 0 |
| Price to Book value | 1.06 |
| Price to Sales | 0.38 |
| Price to Cash Flow | -1.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|